IL17A and spondyloarthropathy: Secukinumab targets IL-17A and has demonstrated significant efficacy in managing spondyloarthropathies, including PsA, axSpA, and PsO, and it is accompanied by a favorable safety profile, characterized by a limited incidence of severe adverse events [73,74,75].